1. Presented By Christina Tsien at 2014 ASCO Annual Meeting

2. Current Limitations in the Response Assessment of Anti-Angiogenic Therapy Presented By Christina Tsien at 2014 ASCO Annual Meeting

3. Imaging Changes Following Anti-Angiogenic Therapy Presented By Christina Tsien at 2014 ASCO Annual Meeting

4. Does Reduction in Enhancement Reflect Anti-Tumor Effect? Presented By Christina Tsien at 2014 ASCO Annual Meeting

5. Recurrent GBM treated with Bevacizumab: CE-Δ T1-weighted Subtraction Maps Aid Prediction of Survival in a Multi-Center Clinical Trial Presented By Christina Tsien at 2014 ASCO Annual Meeting

6. Improved Response Rates with Anti-Angiogenic Therapies Does Not Correlate to Improved OS Presented By Christina Tsien at 2014 ASCO Annual Meeting

7. Physiologic MRI: Imaging Tumor Biology May Improve Response Assessment Presented By Christina Tsien at 2014 ASCO Annual Meeting

8. Slide 8 Presented By Christina Tsien at 2014 ASCO Annual Meeting

9. Bi-modal fitted ADC Histogram Analysis Predict 6 mth PFS in Recurrent GBM Tx with Bevacizumab Presented By Christina Tsien at 2014 ASCO Annual Meeting

10. Bevacizumab Decreases Edema Leading to Improved Clinical Benefit Presented By Christina Tsien at 2014 ASCO Annual Meeting

11. Vessel Architectural Imaging Presented By Christina Tsien at 2014 ASCO Annual Meeting

12. Summary Presented By Christina Tsien at 2014 ASCO Annual Meeting

13. Imaging Biomarkers Ready for Prime Time? Presented By Christina Tsien at 2014 ASCO Annual Meeting

14. Physiologic Imaging Biomarkers must add value beyond known Clinical Predictors of OS Presented By Christina Tsien at 2014 ASCO Annual Meeting

15. What are the Challenges in Incorporating Imaging Biomarkers in the Clinic Today? Presented By Christina Tsien at 2014 ASCO Annual Meeting

16. Diffusion MRI Presented By Christina Tsien at 2014 ASCO Annual Meeting

17. Summary Presented By Christina Tsien at 2014 ASCO Annual Meeting